{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of participants who experienced adverse events (AE's) and serious adverse events (SAE's) during the course of the trial according to CTCAE (4.0)","groups":[{"description":"Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants enrolled in trial and given treatment. See AE section for details.","reportingStatus":"POSTED","timeFrame":"up to 2 yrs after treatment","title":"Toxicities, Number of Persons With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}